Zhejiang Orient Gene Biotech has been focused on protecting inventions in United States(US) with 16 publications in Q3 2023

The United States(US) Patent Office dominates the patent filings and grants with nearly 17% filings and 68% grants. The China(CN), United States(US), Canada(CA), and European Patent Office (EP) patent Office are among the top ten patent offices where Zhejiang Orient Gene Biotech is filings its patents. Among the top granted patent authorities, Zhejiang Orient Gene Biotech has 68% of its grants in United States(US), 26% in China(CN), and 5% in Canada(CA).

Fujifilm could be the strongest competitor for Zhejiang Orient Gene Biotech

Fujifilm and Sekisui Chemical secured the top positions according to recent patent publication data.

Patents related to industrial automation and healthtech lead Zhejiang Orient Gene Biotech’s portfolio

Zhejiang Orient Gene Biotech has the highest number of patents in industrial automation followed by, healthtech and climate change. For industrial automation, nearly 50% of patents were filed and 0% of patents were granted in Q3 2023.

First aid and wound care related patents lead Zhejiang Orient Gene Biotech portfolio followed by general surgery devices, and hospital supplies

Zhejiang Orient Gene Biotech has highest number of patents in first aid and wound care followed by general surgery devices, hospital supplies, and . For first aid and wound care, nearly 33% of patents were filed and 0% of patents were granted in Q3 2023.

For comprehensive analysis of Zhejiang Orient Gene Biotech’s filings and grants, buy the databook here.

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

Be better informed